Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis

Bai,Xiangdong; Zhang,Shengxiao; Qiao,Jun; Xing,Xiaolong; Li,Weina; Zhang,Huanhu; Xie,Jun

doi:10.3892/mmr.2021.12085

Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis

Authors:
- Xiangdong Bai
- Shengxiao Zhang
- Jun Qiao
- Xiaolong Xing
- Weina Li
- Huanhu Zhang
- Jun Xie
View Affiliations

Affiliations: Department of Breast Surgery, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi 030013, P.R. China, Department of Rheumatism and Immunology, Second Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Research and Development Division, Shanxi Immune Medical Technology Co., Ltd., Taiyuan, Shanxi 030001, P.R. China, Department of Radiotherapy, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Gastroenterology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi 030013, P.R. China, Department of Biochemistry and Molecular Biology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: April 12, 2021 https://doi.org/10.3892/mmr.2021.12085
Article Number: 446
Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA (lncRNA) second chromosome locus associated with prostate‑1 (SChLAP1), also named LINC00913, has been reported to accelerate the carcinogenesis of prostate cancer. The aim of this study was to explore the role and mechanism of SChLAP1 in triple negative breast cancer (TNBC). The expression of SChLAP1 in TNBC tissues and cells was determined by reverse transcription quantitative PCR. The effects of SChLAP1 on the growth of TNBC cells was evaluated by detecting cell viability, colony formation and apoptosis. The present study determined that SChLAP1 was upregulated in TNBC tissues and was associated with the long‑distant lymph node metastasis of patients with TNBC. Knockdown of SChLAP1 significantly inhibited cell viability and colony formation, and triggered apoptosis of TNBC cells. Bioinformatics analysis suggested that SChLAP1 acted as a sponge of microRNA (miR)‑524‑5p and negatively modulated the expression of miR‑524‑5p. An inverse correlation was also identified between the expression levels of SChLAP1 and miR‑524‑5p in TNBC tissues. Furthermore, the results demonstrated that SChLAP1 interacted with miR‑524‑5p, and subsequently regulated the expression level of High Mobility Group AT‑Hook 2 (HMGA2) in TNBC cells. It was also found that the overexpression of HMGA2 rescued the suppressed viability of TNBC cells induced by SChLAP1 knockdown. In conclusion, the present findings demonstrated that SChLAP1 modulated the malignant tumor behaviors of TNBC cells by regulating HMGA2 and subsequently restraining miR‑524‑5p.

View Figures

View References

1	Medina MA, Oza G, Sharma A, Arriaga LG, Hernandez Hernandez JM, Rotello VM and Ramirez JT: Triple-negative breast cancer: A review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health. 17:20782020. View Article : Google Scholar : PubMed/NCBI
2	da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG and de Melo AC: Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 145:1028552020. View Article : Google Scholar : PubMed/NCBI
3	Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB and Que FVF: Triple negative breast cancer and platinum-based systemic treatment: A meta-analysis and systematic review. BMC Cancer. 19:10652019. View Article : Google Scholar : PubMed/NCBI
4	De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S: Treatment of triple negative breast cancer (TNBC): Current options and future perspectives. Cancer Treat Rev. 36 (Suppl 3):S80–S86. 2010. View Article : Google Scholar
5	Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI
6	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
7	Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
8	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
11	Rodriguez Bautista R, Ortega Gómez A, Hidalgo Miranda A, Zentella Dehesa A, Villarreal-Garza C, Ávila-Moreno F and Arrieta O: Long non-coding RNAs: Implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. Clin Epigenetics. 10:882018. View Article : Google Scholar : PubMed/NCBI
12	Wang Q, Gao S, Li H, Lv M and Lu C: Long noncoding RNAs (lncRNAs) in triple negative breast cancer. J Cell Physiol. 232:3226–3233. 2017. View Article : Google Scholar : PubMed/NCBI
13	Kong X, Liu W and Kong Y: Roles and expression profiles of long non-coding RNAs in triple-negative breast cancers. J Cell Mol Med. 22:390–394. 2018. View Article : Google Scholar : PubMed/NCBI
14	Piasecka D, Braun M, Kordek R, Sadej R and Romanska H: MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018. View Article : Google Scholar : PubMed/NCBI
15	Naorem LD, Prakash VS, Muthaiyan M and Venkatesan A: Comprehensive analysis of dysregulated lncRNAs and their competing endogenous RNA network in triple-negative breast cancer. Int J Biol Macromol. 145:429–436. 2020. View Article : Google Scholar : PubMed/NCBI
16	Xu ST, Xu JH, Zheng ZR, Zhao QQ, Zeng XS, Cheng SX, Liang YH and Hu QF: Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. Biomed Pharmacother. 96:14–21. 2017. View Article : Google Scholar : PubMed/NCBI
17	Fan H, Yuan J and Li X, Ma Y, Wang X, Xu B and Li X: LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression. Biomed Pharmacother. 125:1099872020. View Article : Google Scholar : PubMed/NCBI
18	Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, Mucci LA and Chinnaiyan AM: Overexpression of the Long Non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur Urol. 70:549–552. 2016. View Article : Google Scholar : PubMed/NCBI
19	Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, et al: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 45:1392–1398. 2013. View Article : Google Scholar : PubMed/NCBI
20	Li Y, Luo H, Xiao N, Duan J, Wang Z and Wang S: Long noncoding RNA SChLAP1 accelerates the proliferation and metastasis of prostate cancer via targeting miR-198 and promoting the MAPK1 pathway. Oncol Res. 26:131–143. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Shi Z, Nan Y and Li M: Inhibiting malignant phenotypes of the bladder cancer cells by silencing long noncoding RNA SChLAP1. Int Urol Nephrol. 48:711–716. 2016. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21. 2013. View Article : Google Scholar : PubMed/NCBI
24	Liao Y, Smyth GK and Shi W: featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 30:923–930. 2014. View Article : Google Scholar : PubMed/NCBI
25	Chen Y and Wang X: miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 48:D127–D131. 2020. View Article : Google Scholar
26	Ji J, Xu R, Ding K, Bao G, Zhang X, Huang B, Wang X, Martinez A, Wang X, Li G, et al: Long Noncoding RNA SChLAP1 forms a growth-promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-κB signaling. Clin Cancer Res. 25:6868–6881. 2019. View Article : Google Scholar : PubMed/NCBI
27	Thomson DW and Dinger ME: Endogenous microRNA sponges: Evidence and controversy. Nat Rev Genet. 17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
28	Chan JJ and Tay Y: Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 19:3102018. View Article : Google Scholar
29	Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature. 505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
30	Liu H, Chen X, Lin T, Chen X, Yan J and Jiang S: MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways. J Cell Physiol. 234:18382–18391. 2019. View Article : Google Scholar : PubMed/NCBI
31	Liu GH, Liu YH, Yang Z, Zhu AL and Zhao CL: MicroRNA-524-5p suppresses the growth and invasive abilities of gastric cancer cells. Oncol Lett. 11:1926–1932. 2016. View Article : Google Scholar : PubMed/NCBI
32	Zhu CY, Meng FQ and Liu J: MicroRNA-524-5p suppresses cell proliferation and promotes cell apoptosis in gastric cancer by regulating CASP3. Eur Rev Med Pharmacol Sci. 23:7968–7977. 2019.PubMed/NCBI
33	Zhen W, Qiu D, Zhiyong C, Xin W, Mengyao J, Dimin Z, Chonghui H, Haijun W and Yonghong Z: MicroRNA-524-5p Functions as a tumor suppressor in a human pituitary tumor-derived cell line. Horm Metab Res. 49:550–557. 2017. View Article : Google Scholar : PubMed/NCBI
34	Zhao K, Wang Q, Wang Y, Huang K, Yang C, Li Y, Yi K and Kang C: EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas. Cancer Lett. 406:12–21. 2017. View Article : Google Scholar : PubMed/NCBI
35	Zhang S, Mo Q and Wang X: Oncological role of HMGA2 (Review). Int J Oncol. 55:775–788. 2019.PubMed/NCBI
36	De Martino M, Fusco A and Esposito F: HMGA and Cancer: A review on patent literatures. Recent Pat Anticancer Drug Discov. 14:258–267. 2019. View Article : Google Scholar : PubMed/NCBI
37	Huang YM, Cheng CH, Pan SL, Yang PM, Lin DY and Lee KH: Gene expression signature-based approach identifies antifungal drug ciclopirox as a novel inhibitor of HMGA2 in colorectal cancer. Biomolecules. 9:6882019. View Article : Google Scholar : PubMed/NCBI
38	Kang NN, Ge SL, Zhang RQ, Huang YL, Liu SD and Wu KM: MiR-490-3p inhibited the proliferation and metastasis of esophageal squamous cell carcinoma by targeting HMGA2. Eur Rev Med Pharmacol Sci. 22:8298–8305. 2018.PubMed/NCBI
39	Xing F, Song Z and He Y: MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2. Biol Res. 51:502018. View Article : Google Scholar : PubMed/NCBI
40	Sun J, Qiao Y, Song T and Wang H: MiR495 suppresses cell proliferation by directly targeting HMGA2 in lung cancer. Mol Med Rep. 19:1463–1470. 2019.PubMed/NCBI
41	Wang MJ, Zhang H, Li J and Zhao HD: microRNA-98 inhibits the proliferation, invasion, migration and promotes apoptosis of breast cancer cells by binding to HMGA2. Biosci Rep. 38:BSR201805712018. View Article : Google Scholar : PubMed/NCBI
42	Wang J, Liang H, Ge H, Guo X, Gu D and Yuan Y: MicroRNA3633p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage. Mol Med Rep. 19:935–942. 2019.PubMed/NCBI
43	Xu X, Zou H, Luo L, Wang X and Wang G: MicroRNA-9 exerts antitumor effects on hepatocellular carcinoma progression by targeting HMGA2. FEBS Open Bio. 9:1784–1797. 2019. View Article : Google Scholar : PubMed/NCBI
44	Xi X, Teng M, Zhang L, Xia L, Chen J and Cui Z: MicroRNA-204-3p represses colon cancer cells proliferation, migration, and invasion by targeting HMGA2. J Cell Physiol. 235:1330–1338. 2020. View Article : Google Scholar : PubMed/NCBI